Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | PPIG | Q13427 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775174 | 1.00 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1ALDH1A1LMNADRD2 | |
| SCHEMBL24774523 | 0.85 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1ALDH1A1LMNADRD2 | |
| SCHEMBL24775068 | 0.84 | HTR2A (0.40) | LMNAHTR2CMEN1KMT2A | |
| SCHEMBL24774525 | 0.84 | HTR2A (0.40) | LMNAHTR2CMEN1KMT2A | |
| SCHEMBL24774521 | 0.84 | CHRNA7 (0.44) | HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL24775070 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1HTR2CMEN1KMT2A | |
| SCHEMBL24774520 | 0.84 | HCRTR2 (0.46) | DRD2HTR2C | |
| SCHEMBL24775175 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1HTR2CMEN1KMT2A | |
| SCHEMBL24774522 | 0.84 | HTR2A (0.39) | ALDH1A1 | |
| SCHEMBL24774524 | 0.83 | ADRA1A (0.41) | HSP90AA1HSP90AB1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HSP90AA1 444/4885HSP90AB1 160/4885ALDH1A1 3125/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HSP90AA1 444/4885HSP90AB1 160/4885ALDH1A1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.